# US 2004/0082068 A1 · Incorporation and priming function of trnalys in hiv and related viruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082068 A1
- Document ID: US20040082068A1
- Status: Published application
- Kind: A1
- Application number: 10/432,223
- Filed: 2003-11-05
- Published: 2004-04-29
- Earliest claimed: 2003-11-05
- Inventors: Lawrence Kleiman; Shan Chen
- Web page: https://patentgrep.com/patent/US20040082068A1

## CPC

- C12N 9/93: {Ligases (6)}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to the demonstration of a direct relationship between the amount of tRNALys3 packaged into HIV, the amount of tRNALys3 placed onto the reverse transcriptase primer binding site which can initiate reverse transcription, and viral infectivity. The present invention also relates to the incorporation of lysyl tRNA synthase into HIV-1 and to the aminoacylation status of tRNALys3 and its impact on virion incorporation. The present invention also relates to methods of modulating lysyl tRNA synthetase (LysRS)-facilitated processes associated with tRNALys3 priming function of RT, to bioassays to screen and identify compounds which interfere with these processes and to compositions for modulating these processes. In one particular embodiment, the compositions modulate the incorporation of LysRS and/or tRNALys3 into HIV and related virions. The present invention also relates to aaRS-facilitated processes associated with their cognate tRNAaa priming function in other types of retroviruses and to methods, assays and compositions which modulate them.

## Claims

### Claim 1

A method of modulating the incorporation of a tRNA involved in reverse transcriptase (RT) priming into a retroviral virion, comprising a modulation of the activity and/or of the level of a cognate aminoacyl tRNA synthetase, wherein the level and/or activity of said cognate aminoacyl tRNA synthetase in a cell infected by said retrovirus positively correlates with an incorporation of said tRNA into said virion.

### Claim 2 (depends on 1)

The method of claim 1, wherein said tRNA is tRNALys3, said aminoacyl tRNA synthetase is LysRS and said retroviral virion is HIV or SIV.

### Claim 3

A method of targeting a molecule into a retrovirus virion comprising providing said molecule linked to a sufficient number of aminoacyl tRNA synthetase involved in transporting its cognate tRNA into a retroviral vi don of said retrovirus in a cell infected with said retrovirus, whereby incorporation of said aminoacyl tRNA synthetase into said virion enables incorporation of said molecule thereinto.

### Claim 4 (depends on 3)

The method of claim 3, wherein said retrovirus is HIV and said aminoacyl tRNA synthetase is LysRS.

### Claim 5

A chimeric protein capable of being incorporated into HIV or SIV virions, comprising a first and second portion, wherein said first portion comprises a sufficient number of amino acids of an intermediate form of LysRS to enable incorporation of said chimeric protein into said virions.

### Claim 6 (depends on 5)

The chimeric protein of claim 5, wherein said retrovirus is HIV and said aminoacyl tRNA transferase is LysRS.

### Claim 7 (depends on 5)

The chimeric protein of claim 5, wherein said second portion is a polypeptide covalently attached to said first portion.

### Claim 8 (depends on 6)

The chimeric protein of claim 6, wherein said polypeptide fragment comprises an amino acid sequence having an antiviral activity.

### Claim 9 (depends on 8)

The chimeric protein of claim 8, wherein said polypeptide fragment comprises an amino acid sequence which prevents proper virion morphogenesis of said HIV or SIV virions.

### Claim 10

A molecule for interfering with incorporation of a native tRNA involved in reverse transcriptase (RT) priming and/or of its native cognate aminoacyl tRNA synthetase into a retroviral virion, wherein said molecule is expressed in trans with respect to the retroviral genome and comprises one of:
a) an aminoacyl tRNA synthetase incorporation domain;
b) said tRNA molecule involved in RT priming or a variant thereof, and
c) a precursor protein of said retroviral virion;
and wherein said molecule interferes with said incorporation of said tRNA and/or said aminoacyl/tRNA synthetase, into said virion, thereby reducing the infectivity of said retroviral virion.

### Claim 11 (depends on 10)

The molecule of claim 10, wherein said tRNA is tRNALys, said aminoacyl tRNA synthetase is LysRS, said precursor protein selected from Pr55gag and Pr160gag and said retroviral virion is HIV or related viruses.

### Claim 12 (depends on 11)

The molecule of claim 11, wherein said native tRNA involved in RT is tRNALys3 and said HIV is HIV-1.

### Claim 13

A method of screening and selecting an agent that modulates the incorporation of a tRNA and/or a cognate aminoacyl tRNA synthetase thereof into a retroviral virion comprising:
a) incubating a candidate agent with a cell expressing at least a portion of said aminoacyl tRNA synthetase, said portion being sufficient for enabling incorporation into said virion;
wherein said cell also contains said retroviral virion, such that said aminoacyl tRNA synthetase is capable of being incorporated into said virion; and
b) determining the amount of said aminoacyl tRNA synthetase and/or said tRNA incorporated into said virions;
wherein an agent that modulates the incorporation of said aminoacyl tRNA synthetase and/or tRNA into said virion is selected when the amount of incorporated aminoacyl tRNA synthetase and/or said tRNA in the presence of said candidate agent is measurably different than in the absence thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein said tRNA is tRNALys, said aminoacyl tRNA synthetase is LysRS and said retroviral virion is HIV or related viruses.

### Claim 15 (depends on 14)

The method of claim 14, wherein said tRNA is tRNALys3 and said incorporation of said tRNALys3 into said virion is assessed by measuring RT priming function.

### Claim 16

A method for reducing the infectivity of a retrovirus, comprising a reduction in the incorporation of a tRNA involved in RT priming and/or of the cognate aminoacyl tRNA synthetase thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein said tRNA is tRNALys3, said aminoacyl tRNA synthetase is LysRS and said retroviral virion is HIV or related viruses.

### Claim 18

A method of modulating an aminoacyl tRNA synthetase-facilitated process associated with its cognate tRNA priming function of reverse transcriptase (RT) wherein this process is selected from the group consisting of a) cognate tRNA incorporation into the retrovirus virion; b) annealing thereof to the primer binding site (PBS) or other retroviral RNA regions; and c) initiation of RT, comprising a modulation of the activity and/or of the level of said cognate aminoacyl tRNA synthetase, a modulation of said cognate tRNA-aminoacyl tRNA synthetase interaction, a modulation of aminoacyl tRNA-Gag interaction, or a modulation of aminoacylation of cognate tRNA, wherein the level and/or activity of said cognate aminoacyl tRNA synthetase, or aminoacylation level of said cognate tRNA in a cell infected by said retrovirus positively correlates with at least one of a) an incorporation of said tRNA into the virion; b) the placement of said tRNA onto the retroviral genome; and c) infectivity of the retrovirus.

### Claim 19

A method of screening and selecting an agent that modulates the incorporation of a tRNA and/or a cognate aminoacyl tRNA synthetase thereof into a retroviral virion comprising: a) incubating a candidate agent with a cell expressing at least a portion of the aminoacyl tRNA synthetase, said portion being sufficient for enabling incorporation into the virion; wherein the cell also contains the retroviral virion, such that the aminoacyl tRNA synthetase is capable of being incorporated into the virions; and b) determining one of the amount of the aminoacyl tRNA synthetase incorporated into the virion; the amount of said cognate tRNA incorporated into the virion; and the amount of reverse transcriptase (RT) priming in said virion; wherein an agent that modulates the incorporation of the aminoacyl tRNA synthetase and/or tRNA into the virion is selected when the amount of incorporated aminoacyl tRNA synthetase, cognate tRNA, or the level of RT priming in the presence of the candidate agent is measurably different than in the absence thereof.
